FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079957429> ?p ?o ?g. }

• W2079957429 endingPage "295" @default.
• W2079957429 startingPage "294" @default.
• W2079957429 abstract "Just when it seemed all over, the manuscript by Boyce et al.1 examining the pharmacokinetics and pharmacodynamics of single dose administration of netazepide, a peripheral CCK-B (gastrin) receptor antagonist, in normal volunteers will most certainly reinvigorate interest in gastric acid secretion and its pharmacological inhibition. Netazepide appears to be a potent inhibitor of gastric acid secretion with rapid onset and a prolonged duration of action.1 If it can be shown to be both safe and effective as maintenance therapy, it may well give proton pump inhibitors (PPIs) a real run for their money. The PPIs, which irreversibly block the final common path of gastric acid production,2 have been the dominant class of antisecretory drugs for over two decades and their continuing supremacy was all but assured with the demise of the potassium competitive acid blockers (PCABs) (although there may be a comeback for this class of agents too3). In addition, concerns have surfaced recently about potential adverse effects from prolonged PPI use4 which has opened the door to other novel compounds such as netazepide. Of course, much work remains to be done with this agent and there are, as yet, many unanswered questions (some of which the authors may well address in two upcoming manuscripts concerning repetitive dosing of netazepide). For example, will tachyphylaxis develop after repeated administration of this competitive receptor antagonist, a phenomenon that has been well described with histamine H2 receptor antagonists, which act one step further along the gastric acid secretory pathway?5 In addition, the endocrine, neurocrine and paracrine networks that control gastric acid secretion and its feedback are redundant.6 It remains to be seen whether upregulation of other pathways could occur leading to additional loss of efficacy (tolerance) with time. Alternatively, will the drug, which appears to have a long secondary half-life, accumulate after repeated dosing leading to unexpected side effects? Moreover, little is known about the metabolism of this agent which has only been administered to a small cadre of normal volunteers. Will the effect of this agent be predictable in patients or will alterations in metabolism lead to ‘slow’ and ‘fast’ metabolisers and unpredictable antisecretory effects? Finally, will potent ECL-cell inhibition by netazepide lead to G-cell hyperplasia and hypergastrinaemia, with the potential for rebound ECL-cell histamine release and excessive gastric acid production4 on withdrawal of the drug? This possibility is of some interest given current concerns regarding rebound gastric acid hypersecretion in double-blind randomised trials of PPI use vs. placebo in normal volunteers.7, 8 On the other hand, judicious use of netazepide in concert with PPIs may lead to more precise titration of individual antisecretory effects, thereby mitigating ECL-cell hyperplasia and parietal cell hypertrophy. This is an exciting and provocative first-in-human study of a novel compound with significant potential. I fully agree with the authors' conclusions that ‘studies of repeated doses of netazepide are justified’.1 Declaration of personal interests: David Metz has served as a consultant and advisory board member for Novartis, as a consultant for AstraZeneca and Takeda, and has received research funding from Fercica. Declaration of funding interests: None" @default.
• W2079957429 created "2016-06-24" @default.
• W2079957429 creator A5008374258 @default.
• W2079957429 date "2012-07-01" @default.
• W2079957429 modified "2023-09-23" @default.
• W2079957429 title "Commentary: netazepide for gastric acid suppression - another kid on the block?" @default.
• W2079957429 cites W1983208716 @default.
• W2079957429 cites W1996333758 @default.
• W2079957429 cites W2017472773 @default.
• W2079957429 cites W2070624385 @default.
• W2079957429 cites W2079447102 @default.
• W2079957429 cites W2090352309 @default.
• W2079957429 cites W2140190193 @default.
• W2079957429 cites W2162701069 @default.
• W2079957429 doi "https://doi.org/10.1111/j.1365-2036.2012.05183.x" @default.
• W2079957429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22747455" @default.
• W2079957429 hasPublicationYear "2012" @default.
• W2079957429 type Work @default.
• W2079957429 sameAs 2079957429 @default.
• W2079957429 citedByCount "1" @default.
• W2079957429 countsByYear W20799574292012 @default.
• W2079957429 crossrefType "journal-article" @default.
• W2079957429 hasAuthorship W2079957429A5008374258 @default.
• W2079957429 hasBestOaLocation W20799574291 @default.
• W2079957429 hasConcept C126322002 @default.
• W2079957429 hasConcept C168481208 @default.
• W2079957429 hasConcept C170493617 @default.
• W2079957429 hasConcept C2776885963 @default.
• W2079957429 hasConcept C2777504413 @default.
• W2079957429 hasConcept C2780719153 @default.
• W2079957429 hasConcept C49039625 @default.
• W2079957429 hasConcept C71924100 @default.
• W2079957429 hasConcept C98274493 @default.
• W2079957429 hasConceptScore W2079957429C126322002 @default.
• W2079957429 hasConceptScore W2079957429C168481208 @default.
• W2079957429 hasConceptScore W2079957429C170493617 @default.
• W2079957429 hasConceptScore W2079957429C2776885963 @default.
• W2079957429 hasConceptScore W2079957429C2777504413 @default.
• W2079957429 hasConceptScore W2079957429C2780719153 @default.
• W2079957429 hasConceptScore W2079957429C49039625 @default.
• W2079957429 hasConceptScore W2079957429C71924100 @default.
• W2079957429 hasConceptScore W2079957429C98274493 @default.
• W2079957429 hasIssue "3" @default.
• W2079957429 hasLocation W20799574291 @default.
• W2079957429 hasLocation W20799574292 @default.
• W2079957429 hasOpenAccess W2079957429 @default.
• W2079957429 hasPrimaryLocation W20799574291 @default.
• W2079957429 hasRelatedWork W2011189688 @default.
• W2079957429 hasRelatedWork W2030116180 @default.
• W2079957429 hasRelatedWork W2051140372 @default.
• W2079957429 hasRelatedWork W2093296646 @default.
• W2079957429 hasRelatedWork W2168143632 @default.
• W2079957429 hasRelatedWork W2315298139 @default.
• W2079957429 hasRelatedWork W2397315347 @default.
• W2079957429 hasRelatedWork W2413277511 @default.
• W2079957429 hasRelatedWork W2802525230 @default.
• W2079957429 hasRelatedWork W4237845765 @default.
• W2079957429 hasVolume "36" @default.
• W2079957429 isParatext "false" @default.
• W2079957429 isRetracted "false" @default.
• W2079957429 magId "2079957429" @default.
• W2079957429 workType "article" @default.